TABLE 3.
Metabolism and transporter effects of direct-acting antivirals
| Direct-acting antiviral | Metabolism | Transporter effects |
|---|---|---|
| Sofosbuvir | Hepatic; forms active nucleoside analog triphosphate GS461203 | P-gp and BCRP substrate |
| Sofosbuvir-ledipasvira | Slow oxidative metabolism via unknown mechanism | P-gp and BCRP substrate Inhibits P-gp, BCRP, OATP1B1, OATP1B3, and bile salt export pump |
| Sofosbuvir-velpatasvira | Hepatic via CYP2B6, CYP2C8, and CYP3A4 | P-gp and BCRP substrate Inhibits P-gp, BCRP, OATP1B1, OATP1B3, and OATP2B1 |
| Ritonavir-boosted paritaprevir-omibitasvir-dasabuvirb |
Ritonavir-boosted
paritaprevir Hepatic via CYP3A4 (primary) and CYP3A5 Ombitasvir Hydrolysis Dasabuvir Hepatic- via CY2C8 (primary) and CYP2C8 |
Ritonavir-boosted
paritaprevir P-gp, BCRP, OATP1B1, and OATP1B3 substrate Inhibits P-gp, BCRP, UGT1A1, OATP1B1, and OATP1B3 Ombitasvir P-gp and BCRP substrate Inhibits P-gp, BCRP, and UGT1A1 Dasabuvir P-gp and BCRP substrate Inhibits P-gp, BCRP, and UGT1A1 |
| Grazoprevir-elbasvir | Hepatic via CYP3A4 (partial) |
Grazoprevir OATP1B1 and OATP1B3 substrate; transported by P-gp Inhibits BCRP (intestinal level), and CYP3A(weak) Elbasvir Inhibits BCRP (intestinal level) |
| Daclatasvir | Hepatic via CYP3A | CYP3A4 and P-gp substrate Inhibits BCRP, P-gp, OATP1B1, and OATP1B3 (moderate) |
| Simeprevir | Hepatic via CYP3A (primary), CYP2C8, and CYP2C19 | CYP3A4, P-gp, BCRP, OATP1B1, OATP1B3, and
OATP2B1 substrate; transported by OATP1B1 and OATP1B3 Inhibits OATP1B1, OATP1B3, P-gp, BCRP, BSEP, CYP1A2 (mild), and CYP3A4 (mild) |
| Ribavirinc | Hepatic and intracellular | Inhibits CYP1A2 and IMDH |
BCRP, breast cancer resistance protein; CYP, cytochrome P450 enzymatic system; IMDH, inosine monophosphate dehydrogenase; OATP, organic anion transporting polypeptide; P-gp, p-glycoprotein.
Metabolism and transporter effects do not include sofosbuvir; refer to sofosbuvir for information.
Ritonavir has no activity against HCV but is given as a low-dose CYP3A inhibitor to boost paritaprevir concentration.
Ribavirin is often used in combination with DAAs; therefore, it is included to provide a comprehensive overview.